Patents by Inventor Rosanne M. Crooke

Rosanne M. Crooke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
    Publication number: 20140193825
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: January 7, 2014
    Publication date: July 10, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20140194492
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Antisense modulation of apolipoprotein B expression
    Patent number: 8735364
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: May 27, 2014
    Assignee: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
    Publication number: 20140128453
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 8, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Thomas A. Bell, III, Richard Lee
  • Antisense modulation of C-reactive protein expression
    Patent number: 8710023
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: April 29, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Modulation of apolipoprotein (a) expression
    Patent number: 8673632
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: March 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Methods for treating hypercholesterolemia
    Patent number: 8664190
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: March 4, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Modulation of angiopoietin-like 3 expression
    Patent number: 8653047
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: February 18, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee
  • MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
    Publication number: 20130317085
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III.
    Type: Application
    Filed: August 7, 2013
    Publication date: November 28, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Modulation of apolipoprotein C-III expression
    Patent number: 8530439
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: September 10, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Antisense modulation of apolipoprotein B expression
    Patent number: 8492355
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: July 23, 2013
    Assignee: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF CETP EXPRESSION
    Publication number: 20130053430
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a CETP mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or HDL activity and reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: February 28, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Thomas A. Bell, III, Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
    Publication number: 20130023579
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Application
    Filed: January 7, 2011
    Publication date: January 24, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • MODULATION OF APOLIPOPROTEIN(A) EXPRESSION
    Publication number: 20120316219
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Application
    Filed: January 18, 2012
    Publication date: December 13, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF TTC39 EXPRESSION TO INCREASE HDL
    Publication number: 20120270929
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a TTC39 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL and/or decreasing PCSK9 in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate cardiovascular disease, or a symptom thereof.
    Type: Application
    Filed: September 24, 2010
    Publication date: October 25, 2012
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark Graham, Thomas A. Bell
  • ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
    Publication number: 20120115926
    Abstract: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.
    Type: Application
    Filed: August 19, 2011
    Publication date: May 10, 2012
    Applicant: Genzyme Corporation
    Inventors: Richard S. Geary, Zhengrong Yu, Rosanne M. Crooke
  • ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION
    Publication number: 20120077866
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
    Type: Application
    Filed: December 2, 2011
    Publication date: March 29, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20120077865
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: November 22, 2011
    Publication date: March 29, 2012
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. FREIER, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Modulation of apolipoprotein (A) expression
    Patent number: 8138328
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: March 20, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Antisense modulation of apolipoprotein B-expression
    Patent number: RE44760
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: February 11, 2014
    Assignee: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier